lncRNA Erbb4‑IR is downregulated in prostate carcinoma and predicts prognosis
- Authors:
- Published online on: March 16, 2020 https://doi.org/10.3892/ol.2020.11464
- Pages: 3425-3430
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Long non‑coding (lnc) RNA Erbb4-IR has been associated with diabetic renal injury; however, its roles in other diseases remain unknown. Therefore, the present study investigated the involvement of Erbb4‑IR in prostate carcinoma. Reverse transcription‑quantitative PCR was used to analyze gene expression in tissue samples collected from patients with prostate carcinoma. Overexpression experiments via cell transfection were performed to determine the association between Erbb4‑IR and microRNA (miR)‑21. Furthermore, Cell Counting Kit‑8 and cell apoptosis assays were performed to assess cell proliferation and apoptotic rate, respectively. The results revealed that Erbb4‑IR was downregulated in prostate carcinoma tissues compared with adjacent non‑cancerous tissues, and that low expression of Erbb4‑IR in tumor tissues was closely associated with poor survival. Furthermore, miR‑21 was upregulated in prostate carcinoma tissues compared with adjacent non‑cancerous tissues and was inversely associated with Erbb4‑IR expression in tumor tissues. In vitro cell experiments revealed that Erbb4‑IR overexpression resulted in the downregulation of miR‑21, while miR‑21 overexpression did not significantly affect the expression of Erbb4‑IR. Moreover, Erbb4‑IR overexpression increased apoptosis and inhibited the proliferation of prostate carcinoma cells. miR‑21 overexpression resulted in the opposite effect and attenuated the effects of Erbb4‑IR overexpression. Therefore, the results of the present study suggested that lncRNA Erbb4‑IR is downregulated in prostate carcinoma and may inhibit cancer development by downregulating miR‑21.